WHO approval of 2nd malaria vaccine

3 October 2023
mosquito_malaria_dengue_big

The World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG) have recommended for approval R21/Matrix-M malaria vaccine.

This has been developed by the University of Oxford and the Serum Institute of India, and leverages Novavax’ (Nasdaq: NVAX) adjuvant technology, R21/Matrix-M malaria vaccine.

Of note, the vaccine demonstrates high efficacy with a reassuring safety profile, with 75% effectiveness over 12 months in Burkina Faso, Kenya, Mali and Tanzania. Moreover, it can be easily deployed and manufactured at mass scale and modest cost - addressing a significant gap in vaccine supply.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical